复方甲氧那明胶囊联合孟鲁司特钠治疗慢性阻塞性肺疾病的疗效研究

Curative Effect of Compound Methoxyphenamine CapsuleCombined with Montelukast Sodium on Chronic ObstructivePulmonary Disease

目的 探索复方甲氧那明胶囊联合孟鲁司特钠治疗慢性阻塞性肺疾病(COPD)的临床疗效。方法 选取2022年1月至2022年12月间到通许第一医院就诊的100例COPD患者,分为对照组和联合组,每组50例。对照组予以孟鲁司特钠片治疗,联合组在上述方案基础上联合复方甲氧那明胶囊治疗,连续治疗3个月。比较两组患者临床症状消失时间、治疗前后肺部通气功能指标(FEV1、FEV1/FVC)、血清IL-8、IL-17、TNF-α水平及用药安全性。结果 联合组临床症状消失时间短于对照组,差异有统计学意义(P <0.05)。治疗后,两组FEV1、FEV1/FVC均高于治疗前,且联合组高于对照组,差异有统计学意义(P <0.05);两组血清IL-8、IL-17、TNF-α均低于治疗前,且联合组低于对照组,差异有统计学意义(P <0.05);两组均未出现明显不良反应。结论 复方甲氧那明胶囊联合孟鲁司特钠治疗COPD既可改善患者肺部通气功能、缓解患者症状,也可控制患者炎症介质水平,且具有较高的用药安全性。

Objective To explore the clinical curative effect of compound methoxyphenamine capsule combined with montelukast sodium on chronic obstructive pulmonary disease(COPD).Methods A total of 100 patients with COPD who visited Tongxu First Hospital from January 2022 to December 2022 were selected and divided into control group and combination group,with 50 cases in each group.The control group was treated with montelukast sodium tablets,while experimental group was additionally treated with compound methoxyphenamine capsules for 3 months.The disappearance time of clinical symptoms,pulmonary ventilation function indexes(FEV1,FEV1/FVC),serum levels of IL-8,IL-17,TNF-αand drug safety were compared between the two groups before and after treatment.Results The disappearance time of clinical symptoms in combination group was shorter than that in control group,with significant difference(P<0.05).After treatment,FEV1%and FEV1/FVC in both groups were increased,which were higher in combined group than control group,with significant differences(P<0.05).After treatment,levels of serum IL-8,IL-17 and TNF-αin both groups were decreased,which were lower in combined group than control group,with significant differences(P<0.05).During the study,there were no obvious adverse reactions in either group.Conclusion Compound methoxyphenamine capsule combined with montelukast sodium can not only improve lung ventilation function,relieve symptoms,but also control levels of inflammatory mediators in COPD patients,with high medication safety.